Pharma Industrial India - Professional magazine for pharma industry suppliers and lab technology

NEWS ABOUT >

Biotechnology

Clean Rooms

Clinical Trials

Consultants

Digitalization

Drug Discovery & Development

Engineering

Global Pharma

Industrial talks

Ingredients

Lab Equipment

Logistics & Distribution

Manufacturing

Market

Outsourcing

Packaging

Quality / GMP

Regulation

Safety

Last edition

All magazines
Subscribe to our magazine

News about "Adverse Event (AE) monitoring"

Sanofi and Regeneron's Dupixent Meets Key Goals in Allergic Fungal Rhinosinusitis; FDA Grants Priority Review

Phase 3 results show Dupixent significantly improved nasal symptoms and sinus health in patients aged six and above with allergic fungal rhinosinusitis, supporting its FDA priority review.

Adverse Event (AE) Monitoring | 10/11/2025 | By Dineshwori | 113

AskBio Reports Safety Data from AB-1003 LGMD 2I/R9 Study

Data from first cohort of five participants suggest an acceptable safety profile for AB-1003 in participants with Limb-Girdle Muscular Dystrophy (LGMD) 2I/R9, with no dose-limiting toxicities or serious adverse events reported up to 52 weeks post-treatment.

Adverse Event (AE) Monitoring | 13/10/2025 | By Dineshwori

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members